Skip to main content

Industry News


Clinical courses

CR courses


Pharma courses

  • Indian drug manufacturers benefit from Big Pharma interest beyond China Pradip Mahajan Mon, 11/27/2023 - 16:09

    Drugmakers are seeking to limit their reliance on Chinese contractors who produce drugs used in clinical trials and early-stage manufacturing, a move that is benefiting rivals in India, according to interviews with 10 industry executives and experts.

  • Cell Biology Lab inaugurated at Kumar Organic Products Research Centre Rajesh Vagh Fri, 11/17/2023 - 17:00

    Cell Biology Lab was inaugurated at Kumar Organic Products Research Centre on 15th November 2023 by Prof. Dr. Samir K Brahmachari , Former Director General, CSIR.

  • Biocon Biologics receives MHRA, UK Approval for YESAFILI, Biosimilar Aflibercept Rajesh Vagh Fri, 11/17/2023 - 16:54

    Biocon Biologics Limited a subsidiary of Biocon Ltd. has announced that MHRA, Medicines and Healthcare products Regulatory Agency in the UK, has granted marketing authorization for YESAFILI®, a biosimilar of Aflibercept.

    In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU).

  • First oral postpartum depression treatment to cost USD 15,900 Rajesh Vagh Wed, 11/08/2023 - 15:48

    Sage Therapeutics has priced the oral postpartum depression medicine at USD 15,900 for a full 14-day course of treatment which is developed with Biogen. The pricing of medicine has been announced recently, whereas the drug was approved by the FDA in August.

  • Zydus and Lupin sign licensing agreement for co-marketing of Saroglitazar Mg

    Zydus Lifesciences Limited a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces the pill burden and offers the patient more convenience.

  • Zydus acquires UK based LiqMeds Group

    Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

  • Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat

    Sun Pharmaceutical Industries Limited and Zydus Lifesciences Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.

  • Eisai shows trial results for LEQEMBI

    Eisai Co., Ltd and Biogen Inc. announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, Massachusetts, United States and virtually October 24-27, 2023.

  • Sun Pharma skin cancer medicine meets endpoint in phase 3 trial

    Philogen S.p.A and Sun Pharmaceutical Industries Limited are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299). The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm). Patients were allowed to receive approved adjuvant systemic therapies after surgery in both arms.

  • Venus Remedies gets marketing approval for six chemotherapy drugs from the Philippines

    Building upon its sizeable presence in the oncology space in the Association of Southeast Asian Nations (ASEAN) region, Venus Remedies Ltd, a well-known provider of affordable cancer drugs worldwide, has received marketing approval from the Philippines, the second largest ASEAN market, for six key chemotherapy drugs.

Subscribe to Industry News